Biogen (BIIB) — insider trading
Health Care · NASDAQ
Biogen (BIIB) has 24 reported SEC Form 4 insider transactions in our data, including 2 open-market sales among the most recent 24 (latest 2026-10-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Godbout Sean | Officer (Chief Accounting Officer) | Option exercise / conversion (derivative) | 27 | — | $0 | Form 4 |
| 2026-10-02 | Godbout Sean | Officer (Chief Accounting Officer) | Shares withheld for taxes / exercise cost | 8 | $219.88 | $1.8K | Form 4 |
| 2026-10-02 | Godbout Sean | Officer (Chief Accounting Officer) | Option exercise / conversion | 27 | — | $0 | Form 4 |
| 2026-10-01 | Godbout Sean | Officer (Chief Accounting Officer) | Grant / award / vesting (derivative) | 985 | — | $0 | Form 4 |
| 2026-09-01 | Parini Michael | Officer (Chief Legal Officer) | Grant / award / vesting (derivative) | 7,405 | — | $0 | Form 4 |
| 2026-08-04 | Minor Lloyd | Director | Open-market sale | 593 | $200.96 | $119.2K | Form 4 |
| 2026-08-03 | Minor Lloyd | Director | Open-market sale | 593 | $203.34 | $120.6K | Form 4 |
| 2026-06-09 | Freire Maria C | Director | Grant / award / vesting | 2,005 | — | $0 | Form 4 |
| 2026-06-09 | Minor Lloyd | Director | Grant / award / vesting | 1,505 | — | $0 | Form 4 |
| 2026-06-09 | Pangalos Menelas N | Director | Option exercise / conversion (derivative) | 2,370 | — | $0 | Form 4 |
| 2026-06-09 | Pangalos Menelas N | Director | Grant / award / vesting | 1,505 | — | $0 | Form 4 |
| 2026-06-09 | Pangalos Menelas N | Director | Option exercise / conversion | 2,370 | — | $0 | Form 4 |
| 2026-06-09 | Patolawala Monish D | Director | Grant / award / vesting | 1,505 | — | $0 | Form 4 |
| 2026-06-09 | LANGER SUSAN | Director | Grant / award / vesting | 1,505 | — | $0 | Form 4 |
| 2026-06-09 | Mantas Jesus B | Director | Grant / award / vesting | 1,505 | — | $0 | Form 4 |
| 2026-06-09 | Rowinsky Eric K | Director | Grant / award / vesting | 1,505 | — | $0 | Form 4 |
| 2026-06-09 | SHERWIN STEPHEN A | Director | Grant / award / vesting | 1,505 | — | $0 | Form 4 |
| 2026-06-09 | HAWKINS WILLIAM A | Director | Grant / award / vesting | 1,505 | — | $0 | Form 4 |
| 2026-05-01 | Keeney Adam | Officer (Head of Corporate Development) | Option exercise / conversion (derivative) | 939 | — | $0 | Form 4 |
| 2026-05-01 | Keeney Adam | Officer (Head of Corporate Development) | Shares withheld for taxes / exercise cost | 455 | $187.06 | $85.1K | Form 4 |
| 2026-05-01 | Keeney Adam | Officer (Head of Corporate Development) | Option exercise / conversion | 939 | — | $0 | Form 4 |
| 2026-04-01 | Godbout Sean | Officer (Chief Accounting Officer) | Option exercise / conversion (derivative) | 181 | — | $0 | Form 4 |
| 2026-04-01 | Godbout Sean | Officer (Chief Accounting Officer) | Shares withheld for taxes / exercise cost | 54 | $183.78 | $9.9K | Form 4 |
| 2026-04-01 | Godbout Sean | Officer (Chief Accounting Officer) | Option exercise / conversion | 181 | — | $0 | Form 4 |
Ask the chat about BIIB's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Biogen (BIIB).
Last updated 2026-10-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.